Metavone Limited (MTV:ASX) – IPO – Developing Innovative Treatments for Dementia & Hormone-related Cancers

Categories Securities, Unissued Securities
Sale Type Price on Application
Price Guide AUD A$3.5M-$5M Target Raise @ $0.20 per share (EV min. A$9M)
Status: Closed

Summary:

Metavone Limited is a drug discovery and development company focused on the development of therapeutic treatments for dementia and hormone-related cancers. The dementia and hormone-related cancer markets are globally significant and have featured significant growth. MTV is seeking to raise a minimum $3.5M and up to $5M. Via issue of new ordinary shares @ $0.20 per share. The new monies will primarily be used to fund the ongoing research and development of the Company’s Isoflavone Drug Technology compounds. Firm bids due Tues, 18 Oct 2016 at 5pm (AEST).
 

Share this Listing

 

Go Back

PrimaryMarkets

VIEW OUR WEBINARS

eGrowcery Part 3 - eGrowcery Difference, Financials and Q&A
eGrowcery Part 3 - eGrowcery Difference, Financials and Q&A
View Recording

eGrowcery Part 2 - Industry Overview, Channel Fragmentation & Competitive Analysis
eGrowcery Part 2 - Industry Overview, Channel Fragmentation & Competitive Analysis
View Recording

eGrowcery Part 1 - Company and Business Overview
eGrowcery Part 1 - Company and Business Overview
View Recording

SOFI Spritz - Australia’s Aperitivo
SOFI Spritz - Australia’s Aperitivo
View Recording

Deal Snapshot
Deal Snapshot
View Recording

Become a Follower